Azaribine for mycosis fungoides.
D000085:Acetates / Q000627:therapeutic use; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000963:Antimetabolites / Q000009:adverse effects / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000096:biosynthesis; D001772:Blood Cell Count; D002490:Central Nervous System / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D005260:Female; D006400:Hematocrit; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D009963:Orotic Acid / Q000096:biosynthesis; D011693:Purpura / Q000188:drug therapy; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*; D014498:Uracil / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
D000085:Acetates; D000963:Antimetabolites; D014227:Triazines; D001224:Aspartic Acid; D014498:Uracil; D009963:Orotic Acid